Expert Opinion on Therapeutic Patents

SJR Rank #4,196H-index: 98SJR: 1.098Best quartile: Q1
Journal website: aims, scope and author guidelines
Publisher

Taylor and Francis Ltd.

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.350.71.051.4

Subject Categories

  • Drug DiscoveryQ1
  • Medicine (miscellaneous)Q1
  • PharmacologyQ1

Areas: Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Intellectual Property and PatentsDiverse Scientific and Economic StudiesLegal Cases and CommentaryReceptor Mechanisms and SignalingMonoclonal and Polyclonal Antibodies ResearchPeptidase Inhibition and AnalysisCholinesterase and Neurodegenerative DiseasesNeuropeptides and Animal PhysiologyCytokine Signaling Pathways and InteractionsNeuroscience and Neuropharmacology Research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs050100150200

Documents per Year

20222025020406080

Detailed Information

ISSN

1354-3776, 1744-7674

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

4.92

References per Document

97.00

Coverage

1991-2026

Scope

Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.

Metrics from SCImago Journal Rank 2025. View on SCImago